X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
Healthcare
$2.96 +1.49%
+$0.06 today
- Market cap
- $302.26M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
52W Low $1.35High $4.83
Volume 1.12M
Average 0.40M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$85.62M
FY 2025 · Annual
Investing Cash Flow
$8.15M
FY 2025 · Annual
-87.8% YoYFinancing Cash Flow
$238.63M
FY 2025 · Annual
+1075.9% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (88.7M) | (93.87M) | (101.17M) | (37.45M) | (79.2M) |
| Depreciation & Amortization | 1.89M | 513K | 419K | 796K | 1.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 5.2M | 8.69M | 8.2M | 4.3M |
| Change in Working Capital | (1.5M) | 5.74M | 344K | 2.68M | (2.58M) |
| Accounts Receivables | 0 | 0 | 0 | (1.07M) | 497K |
| Inventory | 0 | 0 | 0 | (2.82M) | (1.66M) |
| Accounts Payables | 1.17M | 3.43M | 1.23M | (286K) | (2.98M) |
| Other Working Capital | (2.66M) | 2.31M | (890K) | 6.85M | 1.57M |
| Other Non-Cash Items | 17.4M | 5.32M | (4.8M) | (105.13M) | (9.42M) |
| Operating Cash Flow | (70.91M) | (77.1M) | (96.51M) | (130.9M) | (85.62M) |
| Capital Expenditures | (615K) | (103K) | (60K) | (7.33M) | (3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (16.82M) | (57.13M) | (63.39M) |
| Sales of Investments | 0 | 0 | 2M | 26.45M | 74.54M |
| Other Investing Activities | 0 | 0 | 0 | 98M | 0 |
| Investing Cash Flow | (615K) | (103K) | (14.88M) | 66.99M | 8.15M |
| Debt Repayment | 0 | (795K) | 20.44M | 20M | 0 |
| Common Stock Issued | 76.25M | 122.63M | 60M | 294K | 238.53M |
| Common Stock Repurchased | (2M) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.61M) | 8.08M | 0 | 98K |
| Financing Cash Flow | 74.25M | 117.23M | 88.52M | 20.29M | 238.63M |
| Effect of Forex Changes | 90K | (105K) | 99K | (156K) | 213K |
| Net Change in Cash | 2.82M | 39.92M | (22.78M) | (43.77M) | 161.38M |
| Free Cash Flow | (71.52M) | (77.21M) | (96.57M) | (138.23M) | (88.62M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$79.2M
+ D&A$1.3M
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
- Working Capital-$2.6M
- Other Non-Cash-$9.4M
= Operating Cash Flow-$85.6M
- Capex-$3.0M
= Free Cash Flow-$88.6M
Analysis
FY2025 free cash flow is -$88.6M. FCF conversion is 111.9% of net income. Operating cash flow was -$85.6M, with capex of -$3.0M. The largest bridge item is Other Non-Cash at -$9.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 19, 2026 | |
| 8-K | Current report | Oct 8, 2026 |
Does XFOR generate free cash flow?
X4 Pharmaceuticals, Inc. (XFOR) generated -$88.62M of free cash flow in fiscal 2025.
How much operating cash flow does XFOR produce?
Operating cash flow was -$85.62M, before capital expenditures of $3.00M.
Continue the stock analysis
Jump to another research area for this company.